Targeted therapy in refractory thyroid cancer: Current achievements and limitations

Future Oncology

Volumn 7, Issue 5, 2011, Pages 657-668

  Brilli, Lucia ^a   Pacini, Furio ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

anaplastic thyroid cancer; differentiated thyroid cancer; drug resistance; medullary thyroid cancer; Phase II III trials; targeted therapy; tyrosine kinase inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; AXITINIB; B RAF KINASE; BMS 907351; BORTEZOMIB; CABOZANTINIB; COMBRETASTATIN A4 PHOSPHATE; EVEROLIMUS; LENALIDOMIDE; LENVATINIB; MOTESANIB; PACLITAXEL; PAZOPANIB; PLACEBO; PROTEIN TYROSINE KINASE INHIBITOR; SELUMETINIB; SEMAXANIB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; THALIDOMIDE; TIPIFARNIB; UNCLASSIFIED DRUG; VANDETANIB; VEMURAFENIB; XL 184;

ADVANCED CANCER; ANAPLASTIC CARCINOMA; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; DIARRHEA; DIFFERENTIATED THYROID CANCER; DRUG EFFICACY; DRUG ERUPTION; DRUG TARGETING; DRUG TOLERABILITY; FATIGUE; GENE MUTATION; HEAD AND NECK CANCER; HUMAN; HYPERTENSION; NAUSEA; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID PAPILLARY CARCINOMA;

ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; PROTEIN-TYROSINE KINASES; THYROID NEOPLASMS;

EID: 79956147587     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.11.30     Document Type: Review

References (71)

1. Edwards BK, Ward E, Kohler BA, et al.: Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 116(3), 544-573 (2010).
2. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur. J. Endocrinol. 154(6), 787-803 (2006). (Pubitemid 43997716)
3. Cooper DS, Doherty GM, Haugen BR, et al.: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19(11), 1167-214 (2009).
4. Durante C, Haddy N, Baudin E, et al.: Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin. Endocrinol. Metab. 91(8), 2892-2899 (2006). (Pubitemid 44271732)
5. Modigliani E, Cohen R, Campos JM, et al.: Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe détude des tumeurs à calcitonine. Clin. Endocrinol. 48(3), 265-273 (1998). (Pubitemid 28137636)
6. Brandi ML, Gagel RF, Angeli A, et al.: Guidelines for diagnosis and therapy of MEN type 1 and type 2. J. Clin. Endocrinol. Metab. 86(12), 5658-5671 (2001). (Pubitemid 33152604)
7. Schlumberger M, Pacini F: Anaplastic thyroid cancer. In: Thyroid Tumors. Edition Nucléon, France, 303-312 (2006).
8. Fagin JA, Mitsiades N: Molecular pathology of thyroid cancer: diagnostic and clinical implications. Best Pract. Res. Clin. Endocrinol. Metab. 22(6), 955-969 (2008).
9. Nikiforova MN, Nikiforov YE: Molecular diagnostics and predictors in thyroid cancer. Thyroid 19(12), 1351-1361 (2009).
10. Wang Y, Hou P, Yu H, et al.: High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J. Clin. Endocrinol. Metab. 92(6), 2387-2390 (2007). (Pubitemid 46997152)
11. Weinstein IB, Joe A: Oncogene addiction. Cancer Res. 68(9), 3077-3080 (2008).
12. Lin JD, Chao TC: Vascular endothelial growth factor in thyroid cancers. Cancer Biother. Radiopharm. 20(6), 648-661 (2005).
13. Capp C, Wajner SM, Siqueira DR, Brasil BA, Meurer L, Maia AL: Increased expression of vascular endothelial growth factor and its receptors, VEGFR-1 and VEGFR-2, in medullary thyroid carcinoma. Thyroid 20(8), 863-871 (2010).
14. Yu XM, Lo CY, Chan WF, Lam KY, Leung P, Luk JM: Increased expression of vascular endothelial growth factor C in papillary thyroid carcinoma correlates with cervical lymph node metastases. Clin. Cancer Res. 11(22), 8063-8069 (2005). (Pubitemid 41698749)
15. Jo YS, Li S, Song JH, et al.: Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J. Clin. Endocrinol. Metab. 91(9), 3667-3670 (2006). (Pubitemid 44402153)
16. Klein M, Vignaud JM, Hennequin V, et al.: Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J. Clin. Endocrinol. Metab. 86(2), 656-658 (2001). (Pubitemid 32207476)
17. Druker BJ, Guilhot F, OBrien SG, et al.: Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N. Engl. J. Med. 355(23), 2408-2417 (2006). (Pubitemid 44903745)
18. Sierra JR, Cepero V, Giordano S: Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy. Mol. Cancer 9(75), 1-13 (2010).
19. Rosen LS, Kurzrock R, Mulay M, et al.: Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors. J. Clin. Oncol. 25(17), 2369-2376 (2007). (Pubitemid 46999207)
20. Sherman SI, Wirth LJ, Droz JP, et al.: Motesanib diphosphate in progressive differentiated thyroid cancer. N. Engl. J. Med. 359(1), 31-42 (2008). (Pubitemid 351931094)
21. Schlumberger MJ, Elisei R, Bastholt L, et al.: Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J. Clin. Oncol. 27(23), 3794-3801 (2009).
22. Bass MB, Sherman SI, Schlumberger MJ, et al.: Biomarkers as predictors of response to treatment with motesanib in patients with progressive advanced thyroid cancer. J. Clin. Endocrinol. Metab. 95(11), 5018-5027 (2010).
23. Cohen EE, Needles BM, Cullen KJ, et al.: Phase II study of sunitinib in refractory thyroid cancer. Presented at: 2008 ASCO Annual Meeting. Chicago, IL, USA, 30 May-3 June 2008 (Abstract 6025).
24. De Souza JA, Busaidy N, Zimrin A, et al.: Phase II trial of sunitinib in medullary thyroid cancer (MTC). Presented at: 2010 ASCO Annual Meeting. Chicago, USA, 4-8 June 2010 (Abstract 5504).
25. Carr LL, Mankoff D, Goulart BH, et al.: Phase II study of sunitinib in FDG-PET positive, differentiated thyroid cancer and metastatic medullary carcinoma of thyroid with functional imaging correlation. Clin. Cancer Res. 16(21), 5260-5268 (2010).
26. Ravaud A, De La Fouchardiére C, Asselineau J, et al.: Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of Phase II THYSU. Oncologist 15, 212-213 (2010).
27. Carlomagno F, Santoro M: Identification of RET kinase inhibitors as potential new treatment for sporadic and inherited thyroid cancer. J. Chemother. 16, 49-51 (2004). (Pubitemid 40065281)
28. Wells SA Jr, Gosnell JE, Gagel RF, et al.: Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Oncol. 28(5), 767-772 (2010).
29. Robinson BG, Paz-Ares L, Krebs A, Vasselli J, Haddad R: Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J. Clin. Endocrinol. Metab. 95(6), 2664-2671 (2010).
30. Wells SA, Robinson BG, Gagel RF, et al.: Vandetanib in locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trial (ZETA). Presented at: 14th International Thyroid Congress. Oral Communication 021. Paris, France 11-16 September 2010.
31. Leboulleux S, Bastholt L, Krause TM, et al.: Vandetanib in locally advanced or metastatic differentiated thyroid cancer (papillary or follicular; DTC): a randomized, double-blind Phase II trial. Presented at: 14th International Thyroid Congress. Oral Communication 023. Paris, France 11-16 September 2010.
32. Rugo HS, Herbst RS, Liu G, et al.: Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J. Clin. Oncol. 23(24), 5474-5483 (2005).
33. Cohen EE, Rosen LS, Vokes EE, et al.: Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study. J. Clin. Oncol. 26(29), 4708-4713 (2008).
34. Kurzrock R, Cohen EE, Sherman SI, et al.: Long-term results in a cohort of medullary thyroid cancer (MTC) patients (pts) in a Phase I study of XL-184 (BMS 907351), an oral inhibitor of MET, VEGFR2, and RET. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010 (Abstract 5502).
35. Gupta-Abramson V, Troxel AB, Nellore A, et al.: Phase II trial of sorafenib in advanced thyroid cancer. J. Clin. Oncol. 26(29), 4714-4719 (2008).
36. Kloos RT, Ringel MD, Knopp MV, et al.: Phase II trial of sorafenib in metastatic thyroid cancer. J. Clin. Oncol. 27(10), 1675-1684 (2009).
37. Hoftijzer H, Heemstra KA, Morreau H, et al.: Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur. J. Endocrinol. 161(6), 923-931 (2009).
38. Lam ET, Ringel MD, Kloos RT, et al.: Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 28(14), 2323-2330 (2010).
39. Capdevila J, Iglesias L, Halperin I, et al.: Sorafenib in patients (pts) with advanced thyroid carcinoma (TC): a compassionate use program. J. Clin. Oncol. 28(Suppl. 15) (2010) (Abstract 5590).
40. Bible KC, Suman VJ, Molina JR, et al.: Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a Phase 2 consortium study. Lancet Oncol. 11(10), 962-972 (2010).
41. Flaherty K, Puzanov I, Sosman J, et al.: Phase I study of PLX4032: proof of concept for V600E BRAF mutation as a therapeutic target in human cancer. J. Clin. Oncol. 27(Suppl. 15) (2009) (Abstract 9000).
42. Lucas AS, Cohen EE, Cohen RB, et al.: Phase II study and tissue correlative studies of AZD6244 (ARRY-142886) in iodine-131 refractory papillary thyroid carcinoma (IRPTC) and papillary thyroid carcinoma (PTC) with follicular elements. J. Clin. Oncol. 28(Suppl. 15) (2010) (Abstract 5536).
43. Maitland ML, Bakris GL, Black HR, et al.: Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signalling pathway inhibitors. J. Natl Cancer Inst. 102(9), 596-604 (2010).
44. Lacouture ME, Wu S, Robert C, et al.: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9), 1001-1011 (2008).
45. Illouz F, Laboureau-Soares S, Dubois S, Rohmer V, Rodien P: Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur. J. Endocrinol. 160 (3), 331-336 (2009).
46. Lu JF, Claret L, Sutjandra L, et al.: Population pharmacokinetic/ pharmacodynamic modeling for the time course of tumor shrinkage by motesanib in thyroid cancer patients. Cancer Chemother. Pharmacol. 66(6), 1151-1158 (2010).
47. Fizazi K, Lipton A, Mariette X, et al.: Randomized Phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J. Clin. Oncol. 27(10), 1564-1571 (2009).
48. Lipton A, Steger GG, Figueroa J, et al.: Randomized active-controlled Phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases. J. Clin. Oncol. 25(28), 4431-4437 (2007). (Pubitemid 350013849)
49. Schweppe RE, Kerege AA, French JD, Sharma V, Grzywa RL, Haugen BR: Inhibition of Src with AZD0530 reveals the Src-Focal Adhesion kinase complex as a novel therapeutic target in papillary and anaplastic thyroid cancer. J. Clin. Endocrinol. Metab. 94(6), 2199-2203 (2009).
50. Liu Z, Falola J, Zhu X, et al.: Antiproliferative effects of Src inhibition on medullary thyroid cancer. J. Clin. Endocrinol. Metab. 89(7), 3503-3509 (2004). (Pubitemid 38951927)
51. Mooney CJ, Nagaiah G, Fu P, et al.: A Phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome. Thyroid 19(3), 233-240 (2009).
52. Liu Z, Hou P, Ji M, et al.: Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J. Clin. Endocrinol. Metab. 93(8), 3106-3116 (2008).
53. Mitsiades CS, McMillin D, Kotoula V, et al.: Antitumor effects of the proteasome inhibitor bortezomib in medullary and anaplastic thyroid carcinoma cells in vitro. J. Clin. Endocrinol. Metab. 91(10), 4013-4021 (2006). (Pubitemid 44536879)
54. Harvey RD, Kauh JS, Ramalingam SS, et al.: Combination therapy with sunitinib and bortezomib in adult patients with radioiodine refractory thyroid cancer. Presented at: 2010 ASCO Annual Meeting. Chicago, IL, USA, 4-8 June 2010 (Abstract 5589).
55. Ain KB, Lee C, Williams KD: Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. Thyroid 17(7), 663-670 (2007). (Pubitemid 47311556)
56. Ain KB, Lee C, Holbrook KM, Dziba JM, Williams KD: Phase II study of lenalidomide in distantly metastatic, rapidly progressive, and radioiodine-unresponsive thyroid carcinomas: preliminary results. Presented at: 2008 ASCO Annual Meeting. Chicago, IL, USA 30 May-3 June 2008 (Abstract 6027).
57. Cabanillas ME, Kurzrock R, Sherman SI: Phase I trial of combination sorafenib and tipifarnib: the experience in advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). J. Clin. Oncol. 28, (Suppl. 15) (2010) (Abstract 5586).
58. Efficacy of XL184 (Cabozantinib) in Advanced Medullary Thyroid Cancer (EXAM) (NCT00704730) http://clinicaltrials.gov/ct2/show/NCT007 04730?term=NCT00704730&rank=1
59. Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer (NCT00984282) http://clinicaltrials.gov/ct2/show/ NCT009 84282?term=NCT00984282&rank=1
60. Evaluating the Safety and Efficacy of Oral E7080 in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology (NCT00784303) http://clinicaltrials.gov/ct2/show/NCT0078 4303?term=NCT00784303&rank=1
61. Balagula Y, Lacouture ME, Cotliar J: Dermatologic Toxicities of targeted Anticancer Therapies www.SupportiveOncology.net 8, 149-160 (2010).
62. Study of Combretastatin and Paclitaxel/ Carboplatin in the Treatment of Anaplastic Thyroid Cancer (NCT00507429) http://clinicaltrials.gov/ct2/show/ NCT0050 7429?term=NCT00507429&rank=1
63. Everolimus in Treating Patients With Progressive or Recurrent, Unresectable, or Metastatic Thyroid Cancer (NCT01118065) http://clinicaltrials. gov/ct2/show/NCT011 18065?term=NCT01118065&rank=1
64. Everolimus in Treating Patients With Locally Advanced or Metastatic Thyroid Cancer (NCT01164176) http://clinicaltrials.gov/ct2/show/NCT01164 176?term=NCT01164176&rank=1
65. RAD001 for Patients With Radioiodine Refractory Thyroid Cancer (NCT00936858) http://clinicaltrials.gov/ct2/show/NCT0093 6858?term= NCT00936858&rank=1
66. Evaluating the Combination of Everolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (NCT01141309) http://clinicaltrials.gov/ct2/show/NCT011413 09?term=NCT01141309&rank=1
67. Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone (NCT01263951) http://clinicaltrials. gov/ct2/show/NCT012639 51?term=NCT01263951&rank=1
68. Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer (NCT01025453) http://clinicaltrials.gov/ct2/ show/NCT01025 453?term=NCT01025453&rank=1
69. Tipifarnib and Sorafenib in Treating Patients With Advanced Cancer (NCT00244972) http://clinicaltrials.gov/ct2/show/NCT002 44972?term= NCT00244972&rank=1
70. SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck (NCT00005647) http://clinicaltrials.gov/ct2/show/NCT000 05647?term=NCT00005647&rank=1
71. Study of Combretastatin and Paclitaxel/ Carboplatin in the Treatment of Anaplastic Thyroid Cancer (NCT00507429) http://clinicaltrials.gov/ct2/show/ NCT005 07429?term=NCT00507429&rank=1